A Study to Determine Pharmacokinetic Changes of Ceftriaxone in Patients With Liver Cirrhosis
Key facts
- Who runs it
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 10 Jul 2023
- Ended
- 1 Jan 2026
- Type of study
- Observational
- Treatments tested
- No intervention (observational study)
- Record updated
- 8 January 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥18 years
- Clinical, radiological and/or histological diagnosis of liver cirrhosis and portal hypertension
- Presence of ascites
- Receiving ceftriaxone in the context of prophylaxis or treatment of infection
- Indication for diagnostic and/or therapeutic paracentesis
- Providing oral informed consent
Who cannot take part
- None
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The investigators designed an observational multicenter explorative in vivo study to investigate the changes in ceftriaxone pharmacokinetics in blood and ascites. The investigators will include a total of 20 patients with liver cirrhosis admitted to the ward of participating hospitals. Patients are eligible when receiving ceftriaxone and concomitantly receive paracentesis. The investigators will collect all available waste blood samples of each participant, starting from study entry up until 48 hours after the last dosing interval of ceftriaxone. The investigators will collect all available waste ascites samples of each participant up until 48 hours after the last dosing interval of ceftriaxone. Duration of the trial: The study duration is variable and depends on the duration of ceftriaxone treatment and duration of hospital admission, which both are determined by the treating physician and is not influenced by study participation. Patients will be eligible for study inclusion when patients received (a single dose of) ceftriaxone treatment and undergo paracentesis during ceftriaxone treatment. The study will end 48 hours after the last dosing interval of ceftriaxone or until hospital discharge, whichever comes first. Study timeline: The investigators expect to enrol 1-2 participants every month. The total enrolment time will thus be approximately 12 months.
The group in the trial
- observational ceftriaxone
Patiënts with liver cirrhosis receiving ceftriaxone treatment.
Treatment: No intervention (observational study)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Observational Explorative Study to Determine Pharmacokinetic Changes of Ceftriaxone in Blood and Ascites in Patients Admitted With Decompensated Liver Cirrhosis With or Without Renal Impairment.
- Record updated
- 8 January 2026